My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

21.83 -0.46 (-2.06%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

July 09, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 08, 2024

Via Benzinga

The 7 Best Under $10 Stocks to Buy in July 2024 ↗

July 06, 2024

We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.

Via InvestorPlace

Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts ↗

April 12, 2024

Via Benzinga

Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views ↗

February 28, 2024

Via Benzinga

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 20, 2024

Via Benzinga

Have $5-10? 7 Affordable Stocks That Are About to Breakout. ↗

June 13, 2024

These stocks are already showing gains this year, but they are all still affordable stocks ready to breakout.

Via InvestorPlace

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 10, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 05, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 15, 2024

Via Benzinga

NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday ↗

May 15, 2024

Via Benzinga

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket ↗

May 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 15, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 15, 2024

We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!

Via InvestorPlace

ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 14, 2024

ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results ↗

May 14, 2024

Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 14, 2024

Via Benzinga

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

May 13, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

April 29, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Appoints David Topper as Chief Financial Officer

April 10, 2024

Industry veteran with over 40 years of experience in finance, investment management, and investment banking

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday ↗

March 11, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

Via Benzinga

Topics Stocks

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

March 11, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

March 10, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

March 09, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

March 04, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

March 04, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Pricing of $150 Million Public Offering

February 28, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Proposed Public Offering

February 28, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

February 28, 2024

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.